Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.


SecurityEBRYY / Centrais Electricas Brazil (15234Q207)
Institutional Owners53
Institutional Shares8,243,072
Institutional Value$ 54,735,000 USD

Institutional Stock Ownership and Shareholders()

Centrais Electricas Brazil (OTC:EBRYY) has 53 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 8,243,072 shares. Largest shareholders include Goldman Sachs Group Inc, Vanguard Group Inc, Bienville Capital Management, LLC, Arrowstreet Capital, Limited Partnership, Parametric Portfolio Associates Llc, Russell Investments Group, Ltd., Aperio Group, LLC, State Street Corp, UBS Group AG, and Citigroup Inc.
Centrais Electricas Brazil (OTC:EBRYY) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-05-09 13F-HR IFP Advisors, Inc 156 156 0.00 1 1 0.00
2018-05-11 13F-HR CITIGROUP INC 1,024,732 163,418 -84.05 5,841 1,038 -82.23
2018-05-11 13F-HR PNC FINANCIAL SERVICES GROUP, INC. 1,765 3,544 100.79 10 23 130.00
2018-05-11 13F-HR DIMENSIONAL FUND ADVISORS LP 40,692 40,692 0.00 235 258 9.79
2018-05-10 13F-HR JP Morgan Chase & Co 73,447 10,300 -85.98 419 65 -84.49
2018-05-14 13F-HR Renaissance Technologies LLC 46,900 120,700 157.36 267 766 186.89
2018-05-11 13F-HR Russell Investments Group, Ltd. 181,439 273,097 50.52 1,047 1,734 65.62
2018-07-18 13F-HR BOSTON ADVISORS LLC 58,933 59,868 1.59 374 192 -48.66
2018-05-18 13F-HR/A ROYAL BANK OF CANADA 2,000 8,908 345.40 11 57 418.18
2018-05-01 13F-HR COMERICA BANK 58,356 59,169 1.39 364 335 -7.97
2018-05-09 13F-HR BlackRock Inc. 0 32,693 0 208
2018-05-14 13F-HR PARAMETRIC PORTFOLIO ASSOCIATES LLC 124,378 283,384 127.84 709 1,799 153.74
2018-05-08 13F-HR Aperio Group, LLC 220,834 235,022 6.42 1,259 1,492 18.51
2018-05-14 13F-HR PineBridge Investments, L.P. 61,061 59,702 -2.23 348 379 8.91
2017-08-18 13F-HR WFG Advisors, LP 54 54 0.00 0 0
2018-05-14 13F-HR ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 34,022 381,415 1,021.08 194 2,422 1,148.45
2018-05-15 13F-HR Advisor Group, Inc. 1,200 1,200 0.00 7 8 14.29
2018-05-08 13F-HR STEVENS CAPITAL MANAGEMENT LP 0 26,188 0 166
2018-05-15 13F-HR BANK OF AMERICA CORP /DE/ 6,934 8,266 19.21 40 53 32.50
2018-05-18 13F-HR CIBC World Markets Inc. 0 12,372 0 79
2018-05-14 13F-HR Virtu Financial LLC 25,600 0 -100.00 146 0 -100.00
2018-05-08 13F-HR SIGNATUREFD, LLC 4,406 28
2018-05-15 13F-HR UBS Group AG 186,839 181,387 -2.92 1,065 1,152 8.17
2018-05-14 13F-HR MORGAN STANLEY 229,908 11,564 -94.97 1,311 74 -94.36
2018-05-15 13F-HR FIFTH THIRD BANCORP 80 0 -100.00 0 0
2018-05-15 13F-HR BARCLAYS PLC 21,500 102,464 376.58 123 651 429.27
2018-04-20 13F-HR Steward Partners Investment Advisory, Llc 100 100 0.00 0 0
2018-05-14 13F-HR Convergence Investment Partners, LLC 566 4
2018-05-08 13F-HR US BANCORP \DE\ 2,561 2,561 0.00 15 16 6.67
2018-05-09 13F-HR NORTHERN TRUST CORP 42,569 47,029 10.48 242 299 23.55
2018-07-09 13F-HR CENTRAL TRUST Co 500 500 0.00 3 2 -33.33
2018-05-15 13F-HR VANGUARD GROUP INC 1,352,667 1,362,967 0.76 7,710 8,655 12.26
2018-05-14 13F-HR Connor, Clark & Lunn Investment Management Ltd. 55,093 22,493 -59.17 314 143 -54.46
2018-05-11 13F-HR HSBC HOLDINGS PLC 29,389 25,876 -11.95 168 164 -2.38
2018-05-11 13F-HR Mitsubishi UFJ Trust & Banking Corp 45,684 56,272 23.18 260 357 37.31
2018-05-15 13F-HR Banco De Sabadell, S.a 26,455 174
2018-05-11 13F-HR MACQUARIE GROUP LTD 97,500 76,200 -21.85 556 484 -12.95
2018-05-15 13F-HR Bienville Capital Management, LLC 344,106 446,100 29.64 1,961 2,833 44.47
2017-05-08 13F-HR ARXIS SECURITIES LLC 13,364 73
2018-05-11 13F-HR STIFEL FINANCIAL CORP 32,783 32,783 0.00 188 206 9.57
2018-05-11 13F-HR CITADEL ADVISORS LLC 23,210 147
2018-05-15 13F-HR GOLDMAN SACHS GROUP INC 3,638,205 3,633,060 -0.14 20,738 23,070 11.25
2018-05-02 13F-HR WELLS FARGO & COMPANY/MN 3,016 16 -99.47 17 0 -100.00
2018-05-15 13F-HR JANE STREET GROUP, LLC 24,089 13,757 -42.89 141 87 -38.30
2018-05-15 13F-HR DEUTSCHE BANK AG\ 0 8,800 0 55
2018-07-18 13F-HR Cornerstone Advisors, Inc. 371 0 -100.00 2 0 -100.00
2018-05-11 13F-HR BNP PARIBAS ARBITRAGE, SA 412 412 0.00 2,348 2,616 11.41
2018-05-14 13F-HR AMERIPRISE FINANCIAL INC 0 10,975 0 70
2018-06-14 13F-HR/A Dynamic Technology Lab Private Ltd 15,750 100
2018-05-15 13F-HR GUGGENHEIM CAPITAL LLC 49,995 32,115 -35.76 285 203 -28.77
2018-05-15 13F-HR Squarepoint Ops LLC 22,271 141
2018-05-15 13F-HR STATE STREET CORP 140,892 224,298 59.20 803 1,424 77.33
2018-05-15 13F-HR Cubist Systematic Strategies, LLC 20,654 0 -100.00 118 0 -100.00
2018-07-20 13F-HR LS Investment Advisors, LLC 130 130 0.00 1 0 -100.00
2018-05-11 13F-HR Quantbot Technologies LP 1,700 0 -100.00 9 0 -100.00
2018-05-14 13F-HR/A CITADEL ADVISORS LLC 0 23,210 0 147
2017-02-10 13F-HR BlackRock Group LTD 38,660 265
2018-04-30 13F-HR Harel Insurance Investments & Financial Services Ltd. 3,276 2,676 -18.32 19 17 -10.53
2018-04-18 13F-HR/A FNY Partners Fund LP 10,000 0 -100.00 57 0 -100.00
2018-05-10 13F-HR QUADRANT CAPITAL GROUP LLC 497 3

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 15234Q207